Quantcast

Latest colitis Stories

2011-05-19 08:57:00

EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI. The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days...

2011-05-18 00:01:30

The Crohn's & Colitis Foundation of America is hosting a live webinar for caregivers, pediatric healthcare professionals, and children and teens with Crohn's disease to address critical issues about managing and coping with disease. New York, NY (PRWEB) May 17, 2011 WHO: This live and interactive webinar will be of interest to children and teens with Crohn's disease, their caregivers, and healthcare professionals. WHAT: The Crohn's & Colitis Foundation of America is hosting an...

2011-05-10 08:00:00

ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago. Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated...

2011-05-09 15:30:00

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population. The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in...

2011-05-06 00:26:42

Administration of Helicobacter pylori DNA reduces symptoms, new research reveals pathway for future treatments DNA from Helicobacter pylori, a common stomach bacteria, minimizes the effects of colitis in mice, according to a new study by University of Michigan Medical School scientists. The study published in Gut this month was performed by a team of investigators assembled by senior author John Y. Kao, M.D. of the University of Michigan's Division of Gastroenterology and assistant professor...

2011-05-05 16:18:00

Administration of Helicobacter pylori DNA reduces symptoms, new research reveals pathway for future treatments ANN ARBOR, Mich., May 5, 2011 /PRNewswire-USNewswire/ -- DNA from Helicobacter pylori, a common stomach bacteria, minimizes the effects of colitis in mice, according to a new study by University of Michigan Medical School scientists. The study published in Gut this month was performed by a team of investigators assembled by senior author John Y. Kao, M.D. of the University of...

2011-05-05 00:00:31

The Philadelphia/Delaware Valley Chapter of the Crohn's & Colitis Foundation of America (CCFA) will host a Take Steps for Crohn's & Colitis Walk on May 21, 2011 at the Philadelphia Art Museum. Philadelphia, PA (PRWEB) May 04, 2011 On May 21, 2011 at the Philadelphia Art Museum, the Philadelphia/Delaware Valley Chapter of the Crohn's & Colitis Foundation of America (CCFA) will host Take Steps for Crohn's & Colitis Walk, the nation's largest annual walk dedicated to finding...

2011-05-04 08:01:00

CLEVELAND, May 4, 2011 /PRNewswire/ -- Ganeden Biotech announced today that the company will present new in vivo data on the effect of its GanedenBC30 probiotic strain in C. diff infection at the Digestive Disease Week (DDW) conference in Chicago, Ill., from May 7-10, 2011. Jointly with its collaborator, Dr. Leo R. Fitzpatrick, Associate Professor from the Department of Pharmacology, Penn State College of Medicine, Pa., Ganeden will present data on the effect of GanedenBC30 on impacting C....

2011-04-25 08:16:34

(Ivanhoe Newswire) -- Patients with inflammatory bowel disease (IBD) have a greater risk of dying if they become infected with Clostridium difficile, according to a new study. IBD, which includes Crohn's disease and ulcerative colitis, causes symptoms such as abdominal pain and diarrhea. Patients with the condition are often sent to the hospital when they experience severe symptoms. The C. difficile infection is not usually fatal in people who are not already severely ill or elderly. British...

2011-04-20 13:14:56

Patients admitted to hospital with inflammatory bowel disease face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness. IBD, consisting of Crohn's disease and...


Latest colitis Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »
Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.